ERBB2 and adrenal cortex carcinoma: Two key areas are not included in this review: (1) biochemical pathways of potential therapeutic interest that have been evaluated only in preclinical studies and (2) approaches expected to be active in ACC tumors harboring specific sensitizing genomic alterations found only in subsets of ACC (e.g., antihuman epidermal growth factor receptor 2 [HER2] agents for ACC tumors that overexpress HER2).